Symbolbild · KI-generiert
Theralase Technologies Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses.
Company description as published by the issuer via TMX Money.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Theralase Technologies Inc. | TLT | TSXV | 52 Mio. USD |
| ME Therapeutics Holdings Inc. | METX | CSE | 53 Mio. USD |
| TelyRx Holdings Inc. Subordinate Voting Shares | TELY | TSX | 52 Mio. USD |
| NetraMark Holdings Inc. | AIAI | TSX | 53 Mio. USD |
| NexLiving Communities Inc. | NXLV | TSXV | 53 Mio. USD |
| Immutep | IMMP | NASDAQ | 56 Mio. USD |
| Eastwood Bio-Medical Canada Inc. | EBM | TSXV | 48 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.